Literature DB >> 9212744

Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice.

F A van de Loo1, S Kuiper, F H van Enckevort, O J Arntz, W B van den Berg.   

Abstract

Using interleukin (IL)-6-deficient (IL-6(0/0) mice or wild-type mice, we investigated the controversial role of IL-6 in joint inflammation and cartilage pathology during zymosan-induced arthritis (ZIA). Monoarticular arthritis was elicited by injection of zymosan into the right knee joint cavity. Production of IL-1, tumor necrosis factor (TNF), IL-6, and nitric oxide by the inflamed knee was assessed in washouts of joint capsule specimens. Plasma corticosterone was measured using a radioimmunoassay. Proteoglycan synthesis was assessed using [35S]sulfate incorporation into patellas ex vivo. Joint swelling was quantified by joint uptake of circulating 99mTechnetium pertechnetate. Histology was taken to evaluate cellular infiltration and cartilage damage. Zymosan caused a rapid increase in articular IL-1, IL-6, TNF, and NO levels. Except for IL-6, the released amounts and time course of these mediators were comparable in the IL-6-deficient mice and the wild-type mice. Elevated plasma corticosterone levels were measured during the first day of arthritis in both strains. At day 2 of ZIA, joint inflammation (joint swelling and cell exudate) in IL-6-deficient mice was comparable with that in the wild-type mice. The marked suppression of chondrocyte proteoglycan synthesis and proteoglycan degradation were on the average higher in the IL-6-deficient mice. Together this resulted in a more pronounced proteoglycan depletion in the IL-6-deficient mice as compared with the wild-type mice during the first week of arthritis. Injection of recombinant IL-6 into the joint cavity corrected the IL-6 deficiency and significantly reduced cartilage destruction. Inflammation was more chronic in the wild-type mice, and these mice also showed a higher prevalence for osteophyte formation. In ZIA, IL-6 plays a dual role in connective tissue pathology, reducing proteoglycan loss in the acute phase and enhancing osteophyte formation in the chronic phase. The latter could be related to the more severe joint inflammation as seen in the normal (IL-6-producing) animals during the chronic phase of arthritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212744      PMCID: PMC1857913     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

1.  Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model.

Authors:  E J von Asmuth; J G Maessen; C J van der Linden; W A Buurman
Journal:  Scand J Immunol       Date:  1990-10       Impact factor: 3.487

Review 2.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

Review 3.  Interleukin-6: historical background, genetics and biological significance.

Authors:  M C Wolvekamp; R L Marquet
Journal:  Immunol Lett       Date:  1990 Mar-Apr       Impact factor: 3.685

4.  The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee.

Authors:  G J van Osch; P M van der Kraan; A A van Valburg; W B van den Berg
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 5.  The biological effects of interleukin 6.

Authors:  B E Barton
Journal:  Med Res Rev       Date:  1996-01       Impact factor: 12.944

6.  Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes.

Authors:  J Flechtenmacher; K Huch; E J Thonar; J A Mollenhauer; S R Davies; T M Schmid; W Puhl; T K Sampath; M B Aydelotte; K E Kuettner
Journal:  Arthritis Rheum       Date:  1996-11

7.  IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection.

Authors:  A K Bromander; L Ekman; M Kopf; J G Nedrud; N Y Lycke
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

8.  Interleukin-1 beta induces synthesis and secretion of interleukin-6 in human chondrocytes.

Authors:  S Bender; H D Haubeck; E Van de Leur; G Dufhues; X Schiel; J Lauwerijns; H Greiling; P C Heinrich
Journal:  FEBS Lett       Date:  1990-04-24       Impact factor: 4.124

9.  Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production.

Authors:  J P Drenth; S H Van Uum; M Van Deuren; G J Pesman; J Van der Ven-Jongekrijg; J W Van der Meer
Journal:  J Appl Physiol (1985)       Date:  1995-11

10.  Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice.

Authors:  Z Chai; S Gatti; C Toniatti; V Poli; T Bartfai
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  30 in total

1.  Interleukin-6 deficiency increases inflammatory bone destruction.

Authors:  K Balto; H Sasaki; P Stashenko
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis.

Authors:  A S de Hooge; F A van De Loo; O J Arntz; W B van Den Berg
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Anti-inflammatory effects of systemic anti-tumour necrosis factor alpha treatment in human/murine SCID arthritis.

Authors:  H Schädlich; J Ermann; M Biskop; W Falk; F Sperling; A Jüngel; J Lehmann; F Emmrich; U Sack
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

4.  Dectin-1 and NOD2 mediate cathepsin activation in zymosan-induced arthritis in mice.

Authors:  Holly L Rosenzweig; Jenna S Clowers; Gabriel Nunez; James T Rosenbaum; Michael P Davey
Journal:  Inflamm Res       Date:  2011-03-20       Impact factor: 4.575

5.  Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models.

Authors:  Matthew D McGeough; Carla A Pena; James L Mueller; Derek A Pociask; Lori Broderick; Hal M Hoffman; Susannah D Brydges
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

6.  Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice.

Authors:  Hiroshi Hata; Noriko Sakaguchi; Hiroyuki Yoshitomi; Yoichiroh Iwakura; Kenji Sekikawa; Yoshiaki Azuma; Chieko Kanai; Eiko Moriizumi; Takashi Nomura; Takashi Nakamura; Shimon Sakaguchi
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 7.  Joint inflammation and cartilage destruction may occur uncoupled.

Authors:  W B van den Berg
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

9.  Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation.

Authors:  K Nissler; D Pohlers; M Hückel; J Simon; R Bräuer; R W Kinne
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 10.  Role of leukotriene B4 receptors in rheumatoid arthritis.

Authors:  Steven Mathis; Venkatakrishna R Jala; Bodduluri Haribabu
Journal:  Autoimmun Rev       Date:  2007-03-30       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.